Comment on CMS-2026-2081-0001
Gilead SciencesSupportBusiness
Summary: Gilead Sciences, Inc. supports the review of the Essential Health Benefits (EHB) framework and advocates for mandatory coverage of all FDA-approved PrEP medications with no cost-sharing. They also recommend broadening prescription drug coverage, prohibiting copay accumulators and maximizers, and ensuring that innovative therapies like CAR T are included in EHB requirements.
Thank you for the opportunity to provide comments on the Essential Health Benefits Request for Information. Our comments are included in the attached letter.